Statin use and endometrial cancer risk: a meta-analysis
Metrics: PDF 1260 views | HTML 1196 views | ?
Jing Yang1,2, Qiaoling Zhu2, Qiao Liu2, Yingxia Wang2, Weimin Xie1 and Lili Hu3
1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Department of Obstetrics and Gynecology, Maternal and Child Health Care Hospital of Hunan Province, Changsha, China
3Department of Obstetrics and Gynecology, Jilin Central Hospital, Jilin, China
Weimin Xie, email: email@example.com
Keywords: statin, endometrial cancer, cancer risk, meta-analysis
Received: March 17, 2017 Accepted: May 04, 2017 Published: June 27, 2017
Several studies have evaluated the association between statin use and endometrial cancer risk. We carried out a meta-analysis of randomized controlled trials (RCTs) and non-randomized studies to evaluate the effect of statins on endometrial cancer risk. A comprehensive search of electronic databases, conference abstracts and clinical trial registers was conducted for published and unpublished results. Studies that evaluated exposure to statins and endometrial cancer risk were considered. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using either a fixed-effects or a random-effects model. Two RCTs and eleven non-randomized studies (four cohort and seven case-control studies) involving 9,517 cases of endometrial cancer were included in the analysis. There was no evidence of an association between statin use and endometrial cancer risk either among RCTs (RR, 0.72; 95% CI, 0.19 to 2.67) or among non-randomized studies (RR, 0.94; 95% CI, 0.82 to 1.07). Combined analysis of all included studies also showed that statin use did not significantly affect endometrial cancer risk (RR, 0.94; 95% CI, 0.82 to 1.07). The sensitivity analysis confirmed the stability of our results. Our findings do not support a protective effect of statins against endometrial cancer at the population level.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.